Results 101 to 110 of about 141,931 (309)

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Concurrent Alzheimer's disease pathology is increasingly recognized as a poor prognostic factor in Parkinson's disease (PD), yet reliable clinical indicators for early identification of AD copathology remain poorly established.
Han Kyu Na, Yeeun Sun, Chan Wook Park, Jung Hyun Lee, Yun Young Choi, Quynh Phuong Vo, Seok Jong Chung, Han Soo Yoo, Chul Hyoung Lyoo, Young H. Sohn, Jin Yong Hong, Phil Hyu Lee   +11 more
wiley   +1 more source

AGRN‐, LRP4‐, MUSK‐Related CMS: Clinical, Neurophysiological, Morphological, Genetic and Pathological Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT Congenital myasthenic syndromes (CMS) are inherited disorders caused by mutations in genes encoding proteins essential for neuromuscular junction (NMJ) function. Pathogenic variants have been identified in more than 35 genes, underscoring the complexity of synaptic biology and the wide range of mechanisms that can compromise neuromuscular ...
Rocio‐Nur Villar‐Quiles, Damien Sternberg, Marie‐Christine Nougues, Arnaud Isapof, Bruno Eymard, Stéphanie Bauché   +5 more
wiley   +1 more source

Lurasidone for the treatment of bipolar depression: an evidence-based review

Neuropsychiatric Disease and Treatment, 2015
Rachel Franklin,1 Sam Zorowitz,1 Andrew K Corse,1 Alik S Widge,2 Thilo Deckersbach1 1Division of Neurotherapeutics, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, 2Picower Institute for Learning and Memory,
Franklin R, Zorowitz S, Corse AK, Widge AS, Deckersbach T   +4 more
doaj  

Presynaptic Congenital Myasthenic Syndromes

Muscle &Nerve, EarlyView.
ABSTRACT Presynaptic congenital myasthenic syndromes (CMS) encompass a large number of rare neurologic disorders caused by impaired release of acetylcholine (ACh) from motor nerve terminals. There are two main groups of presynaptic CMS: one in which the amount of ACh in synaptic vesicles (SV) is diminished and another in which the mechanism of synaptic
Ricardo A. Maselli
wiley   +1 more source

Effects of transection of cervical sympathetic trunk on cognitive function of traumatic brain injury rats

Neuropsychiatric Disease and Treatment, 2019
Juan Long,1 Chunjing He,1 Hong Dai,2 Xinguo Kang,1 Jinfeng Zou,1 Shengli Ye,1 Qian Yu21Department of Pain, Guizhou Province People‘s Hospital, Guiyang, People’s Republic of China; 2Department of Neurology, Guizhou Province People‘s ...
Long J, He CJ, Dai H, Kang XG, Zou JF, Ye SL, Yu Q   +6 more
doaj  

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors.

Circulation Research, 1983
H. Motulsky, M. Snavely, R. J. Hughes, P. Insel   +3 more
semanticscholar   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

A (Alpha1-Adrenergic Receptors), B (Blocking Alpha1-Adrenergic Receptors), C (Catecholamines): On the Road to Heart Failure.

JACC. Basic to translational science
CORRESPONDING AUTHOR: [Figure: see text] FIRST AUTHOR: [Figure: see text]
Roy, Rajika, Koch, Walter J.
openaire   +2 more sources